Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cytek Biosciences (CTKB – Research Report), Elanco Animal Health (ELAN – Research Report) and Atara Biotherapeutics (ATRA – Research Report).
Cytek Biosciences (CTKB)
Goldman Sachs analyst Matthew Sykes maintained a Buy rating on Cytek Biosciences on May 9 and set a price target of $8.00. The company’s shares closed last Tuesday at $6.30.
According to TipRanks.com, Sykes is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytek Biosciences with a $9.38 average price target, implying a 48.4% upside from current levels. In a report issued on May 9, Piper Sandler also maintained a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Elanco Animal Health (ELAN)
In a report issued on May 9, Nathan Rich from Goldman Sachs maintained a Sell rating on Elanco Animal Health, with a price target of $16.00. The company’s shares closed last Tuesday at $17.08, close to its 52-week high of $17.43.
According to TipRanks.com, Rich is a 3-star analyst with an average return of
Currently, the analyst consensus on Elanco Animal Health is a Moderate Buy with an average price target of $19.00.
Atara Biotherapeutics (ATRA)
In a report issued on May 9, Salveen Richter from Goldman Sachs maintained a Sell rating on Atara Biotherapeutics, with a price target of $0.50. The company’s shares closed last Tuesday at $0.60.
According to TipRanks.com, Richter is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Atara Biotherapeutics with a $4.20 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CTKB:
- Cytek Biosciences price target lowered to $8.50 from $10 at Piper Sandler
- Cytek Biosciences backs FY24 revenue view $203M-$213M, consensus $207.89M
- Cytek Biosciences reports Q1 EPS (5c), consensus (4c)
- Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
- Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
